Bimetallic NiCu‐MOF Protects DOX‐Induced Myocardial Injury and Cardiac Dysfunction by Suppressing Ferroptosis and Inflammation
Source abstract
Abstract
Abstract Doxorubicin (DOX), a potent anthracycline chemotherapeutic agent, is widely used in cancer treatment but is associated with significant adverse effects, particularly DOX‐induced cardiomyopathy (DIC). DIC pathogenesis involves the generation of reactive oxygen species (ROS) and ferroptosis induction. Novel therapeutic strategies targeting antioxidant defenses and ferroptosis inhibition are essential for mitigating DIC. An innovative bimetallic metal‐organic framework (MOF), NiCu‐MOF (NCM), is developed, exhibiting multifaceted antioxidant enzyme‐mimicking activities that effectively scavenge a broad spectrum of ROS. Additionally, the bimetallic NCM exhibits excellent iron‐chelating ability. In vitro experiments demonstrate that NCM significantly reduces cardiomyocyte death by attenuating ROS levels and inhibiting ferroptosis. Furthermore, in a mouse model of DIC, NCM treatment results in substantial myocardial protection, evidenced by improved cardiac function and structural integrity. This protective effect is attributed to suppression of ferroptosis, preservation of mitochondrial function, and attenuation of inflammatory responses. Collectively, these findings highlight biocompatible NCM's potential as a novel cardioprotective agent and offer a promising therapeutic strategy for managing DIC.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Peptidase Inhibition and Analysis · Advanced Nanomaterials in Catalysis · Metal-Organic Frameworks: Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Regenerative Medicine of Ministry of Education Institute of Aging and Regenerative Medicine Department of Developmental & Regenerative Medicine College of Life Science and Technology Jinan University Guangzhou 510632 China
School of Pharmacy Shandong Second Medical University Weifang 261053 China
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Shandong Province
References (44)
Show source-provided references
1. 10.1093/annonc/mdn29210.1093/annonc/mdn292 ↗
2. 10.3389/fphar.2018.0126210.3389/fphar.2018.01262 ↗
3. 10.1002/ejhf.116810.1002/ejhf.1168 ↗
4. 10.1016/j.phrs.2021.10546610.1016/j.phrs.2021.105466 ↗
5. 10.1200/JCO.1997.15.4.131810.1200/JCO.1997.15.4.1318 ↗
6. 10.1056/NEJM19980924339130710.1056/NEJM199809243391307 ↗
7. 10.1146/annurev-pharmtox-030620-10484210.1146/annurev-pharmtox-030620-104842 ↗
8. 10.1002/advs.20220600710.1002/advs.202206007 ↗
9. 10.1016/j.redox.2023.10282510.1016/j.redox.2023.102825 ↗
10. 10.1073/pnas.182102211610.1073/pnas.1821022116 ↗
11. 10.1002/advs.20231022710.1002/advs.202310227 ↗
12. 10.1016/j.jconrel.2023.12.03410.1016/j.jconrel.2023.12.034 ↗
13. 10.1016/j.freeradbiomed.2006.02.02410.1016/j.freeradbiomed.2006.02.024 ↗
14. 10.1172/JCI11890910.1172/JCI118909 ↗
15. 10.1039/D3NR01722B10.1039/D3NR01722B ↗
16. 10.1002/smll.20220480910.1002/smll.202204809 ↗
17. 10.1002/advs.20200279710.1002/advs.202002797 ↗
18. 10.1002/advs.20240559710.1002/advs.202405597 ↗
19. 10.1016/j.bioactmat.2022.12.02610.1016/j.bioactmat.2022.12.026 ↗
20. 10.1007/s11427-022-2220-210.1007/s11427-022-2220-2 ↗
21. 10.1002/smll.20190684610.1002/smll.201906846 ↗
22. 10.3390/ijms2409781910.3390/ijms24097819 ↗
23. 10.1002/adma.20170430310.1002/adma.201704303 ↗
24. 10.1021/jacs.3c1060010.1021/jacs.3c10600 ↗
25. 10.1021/jacs.2c0966310.1021/jacs.2c09663 ↗
26. 10.1038/s41467-019-12889-w10.1038/s41467-019-12889-w ↗
27. 10.1021/acs.inorgchem.3c0011810.1021/acs.inorgchem.3c00118 ↗
28. 10.1038/s41467-019-12429-610.1038/s41467-019-12429-6 ↗
29. 10.1038/s41392-024-01969-z10.1038/s41392-024-01969-z ↗
30. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
31. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
32. 10.1172/JCI7293110.1172/JCI72931 ↗
33. 10.1126/scisignal.abn801710.1126/scisignal.abn8017 ↗
34. 10.1016/j.jhazmat.2019.12139010.1016/j.jhazmat.2019.121390 ↗
35. 10.1016/j.semcdb.2019.05.02210.1016/j.semcdb.2019.05.022 ↗
36. 10.1016/j.jacc.2023.02.03910.1016/j.jacc.2023.02.039 ↗
37. 10.3322/caac.2134110.3322/caac.21341 ↗
38. 10.1016/j.redox.2021.10212010.1016/j.redox.2021.102120 ↗
39. 10.1038/s41569-022-00735-410.1038/s41569-022-00735-4 ↗
40. Xia C. K. · Adv. Funct. Mater. · 2021 · 31
41. 10.1021/ie101312k10.1021/ie101312k ↗
42. 10.1021/acsami.4c1967310.1021/acsami.4c19673 ↗
43. 10.7150/thno.8354310.7150/thno.83543 ↗
44. 10.1038/s41418-019-0372-z10.1038/s41418-019-0372-z ↗